Scientist I – Technology Access Program at Alamar Biosciences

Fremont, California, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Life SciencesIndustries

Requirements

Ph.D. in Biochemistry, Molecular Biology, or a related discipline with 0–3 years of relevant industry experience; M.S. with 2–5 years of experience will also be considered
Hands-on experience in executing and optimizing immunoassays such as ELISA. Experience with high-sensitivity platforms (Simoa, MSD, or Luminex) is a plus but not required
Familiarity with molecular biology methods (e.g., qPCR, ddPCR)
Strong problem-solving and analytical skills with attention to detail in experimental execution
Ability to manage time effectively, work collaboratively, and adapt in a fast-paced environment
Strong communication skills, including data presentation and technical documentation
Knowledge of biomarker research, assay validation, or clinical sample testing is desirable
Background in immunology, neuroscience, or proteomics
Ability to manage complex projects in a fast-paced, collaborative environment is highly preferred

Responsibilities

Design, conduct, and analyze single-plex NULISA immunoassay experiments to assess various biomarkers across diverse biological matrices
Design and optimize assay parameters including sensitivity, specificity, detectability, and precision to execute and deliver NULISA immunoassay projects
Troubleshoot technical challenges via root-cause analysis and implement corrective strategies
Collaborate closely with cross-functional teams and external stakeholders to ensure the timely and accurate completion of deliverables
Work cross-functionally across multiple teams including R&D, Sales and Marketing to design, execute and deliver single-plex NULISA immunoassay projects as part of the Technology Access Program

Skills

immunoassay development

NULISA

biomarkers

assay optimization

sensitivity analysis

specificity analysis

root-cause analysis

project management

immunology

neuroscience

proteomics

Alamar Biosciences

Develops technology for protein detection and measurement

About Alamar Biosciences

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company has created NULISA™, a technology that can detect and measure proteins in the human body with high sensitivity and a wide range. This allows researchers and clinicians to profile clinically relevant protein biomarkers, which are essential for developing new diagnostic tests and treatments for various diseases. Alamar's ARGO™ system complements NULISA™ by providing a fully automated, high-throughput platform for precision proteomics. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it more accessible to clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options.

Hayward, CaliforniaHeadquarters

2018Year Founded

$225.7MTotal Funding

GRANTCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

Risks

Increased competition from Olink and SomaLogic may impact Alamar's market share.

Scaling production in Europe and APAC could strain resources and affect quality.

Regulatory hurdles in new regions may delay product launches and affect revenue.

Differentiation

Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection.

The ARGO™ system automates high-throughput proteomics, reducing the need for technical expertise.

Alamar's focus on early disease detection sets it apart in the biotechnology field.

Upsides

ISO 13485:2016 certification boosts Alamar's credibility in the medical device industry.

European expansion with Milan headquarters enhances market reach and client service.

$10M investment accelerates Alzheimer's diagnostics development, strengthening Alamar's market position.

Land your dream remote job 3x faster with AI

Try Jobo Free